{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:08:26Z","timestamp":1783631306474,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.pbb.2022.173433","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T11:03:17Z","timestamp":1658746997000},"page":"173433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Involvement of kynurenine pathway and N-methyl-d-aspartate receptors in the antidepressant-like effect of vilazodone in the tail suspension test in mice"],"prefix":"10.1016","volume":"218","author":[{"given":"Cristina Maria","family":"de Arruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Luiz","family":"Doneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius Vezzi","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozielly Aparecida Lemes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohan Alves Victor","family":"de Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora Luiza","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Alecsander Herane","family":"Rohden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano Gubert","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabr\u00edcio","family":"Rios-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli\u00e2ngela","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziliani","family":"da Silva Buss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Vandresen-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173433_bb0005","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.4088\/JCP.17f11567","article-title":"Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173433_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpsychires.2021.09.057","article-title":"The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway","volume":"144","author":"Camargo","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnins.2014.00012","article-title":"Kynurenines in CNS disease: regulation by inflammatory cytokines","volume":"8","author":"Campbell","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2022.173433_bb0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1742-1241.2011.02885.x","article-title":"Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"66","author":"Citrome","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.pbb.2022.173433_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuro.2012.11.007","article-title":"3-hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system","volume":"34","author":"Colin-Gonzalez","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pbb.2022.173433_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2022.173433_bb0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2022.173433_bb0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/7854_2016_6","article-title":"Role of the kynurenine metabolism pathway in inflammation-induced depression: preclinical approaches","volume":"31","author":"Dantzer","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2022.173433_bb0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pbb.2022.173433_bb0055","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.psyneuen.2010.09.012","article-title":"Inflammation-associated depression: from serotonin to kynurenine","volume":"36","author":"Dantzer","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2022.173433_bb0060","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173433_bb0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3233\/JAD-2011-111097","article-title":"The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression","volume":"28","author":"Dobos","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.pbb.2022.173433_bb0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","article-title":"Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications","volume":"246","author":"Felger","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2022.173433_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbr.2015.07.015","article-title":"Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats","volume":"293","author":"Fischer","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00213-009-1609-1","article-title":"NMDA receptor\/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test","volume":"206","author":"Ghasemi","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173433_bb0085","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.pbb.2022.173433_bb0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2014.03.053","article-title":"Opioid\/NMDA receptors blockade reverses the depressant-like behavior of foot shock stress in the mouse forced swimming test","volume":"735","author":"Haj-Mirzaian","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173433_bb0095","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1007\/s00213-015-4004-0","article-title":"Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests","volume":"232","author":"Haj-Mirzaian","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173433_bb0100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ijnp\/pyx004","article-title":"Distinct antidepressant-like and cognitive effects of antidepressants with different mechanisms of action in middle-aged female mice","volume":"20","author":"Li","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2022.173433_bb0105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/17460441.2017.1362385","article-title":"Animal inflammation-based models of depression and their application to drug discovery","volume":"12","author":"Ma","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.pbb.2022.173433_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.mp.4002148","article-title":"Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice","volume":"14","author":"O'Connor","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173433_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neubiorev.2018.03.023","article-title":"Kynurenine pathway in depression: a systematic review and meta-analysis","volume":"90","author":"Ogyu","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2022.173433_bb0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1471-4159.1998.70010299.x","article-title":"3-hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity","volume":"70","author":"Okuda","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2022.173433_bb0125","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.pbb.2022.173433_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neulet.2014.01.015","article-title":"Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test","volume":"566","author":"Owolabi","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pbb.2022.173433_bb0135","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.102.034280","article-title":"Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist","volume":"302","author":"Page","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173433_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.200","article-title":"Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation","volume":"6","author":"Parrott","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173433_bb0145","first-page":"1","article-title":"Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms","volume":"5","author":"Perez-De La Cruz","year":"2012","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0150","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1038\/s41467-021-25363-3","article-title":"The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter","volume":"12","author":"Plenge","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pbb.2022.173433_bb0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpsychires.2015.05.007","article-title":"Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies","volume":"68","author":"Reus","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173433_bb0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2022.173433_bb0170","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1042\/BST0351287","article-title":"Neurotoxicity of tryptophan metabolites","volume":"35","author":"Smith","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.pbb.2022.173433_bb0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173433_bb0180","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bbi.2011.05.002","article-title":"Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder","volume":"25","author":"Sublette","year":"2011","journal-title":"Brain Behav. Immunol."},{"key":"10.1016\/j.pbb.2022.173433_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12640-017-9714-0","article-title":"Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-alpha, and IL-4 with clinical symptoms during acute relapse of schizophrenia","volume":"32","author":"Szymona","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brainres.2007.09.091","article-title":"Evaluation of glutathione metabolism in NMDA preconditioning against quinolinic acid-induced seizures in mice cerebral cortex and hippocampus","volume":"1184","author":"Vandresen-Filho","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2022.173433_bb0195","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10072-015-2180-7","article-title":"Cerebral cortex, hippocampus, striatum and cerebellum show differential susceptibility to quinolinic acid-induced oxidative stress","volume":"36","author":"Vandresen-Filho","year":"2015","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.pbb.2022.173433_bb0200","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/npp.2013.71","article-title":"NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL\/6J mice","volume":"38","author":"Walker","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2022.173433_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4306\/pi.2015.12.2.155","article-title":"Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action","volume":"12","author":"Wang","year":"2015","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.pbb.2022.173433_bb0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4068\/cmj.2016.52.2.91","article-title":"Vilazodone for the treatment of depression: an update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam Med. J."},{"key":"10.1016\/j.pbb.2022.173433_bb0215","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pharep.2014.12.003","article-title":"Evaluation of the role of NMDA receptor function in antidepressant-like activity. A new study with citalopram and fluoxetine in the forced swim test in mice","volume":"67","author":"Wolak","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pbb.2022.173433_bb0220","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173433_bb0225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.euroneuro.2010.07.011","article-title":"Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test","volume":"20","author":"Zomkowski","year":"2010","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:44:42Z","timestamp":1758775482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"alternative-id":["S0091305722001125"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173433","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of kynurenine pathway and N-methyl-d-aspartate receptors in the antidepressant-like effect of vilazodone in the tail suspension test in mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173433"}}